Recently, the FDA (Food and Drug Administration, US Food and Drug Administration) and a New York-based unicorn company Flatiron (flat iron) focused on health data analysis, trying to use real-world data to prove immunotherapy and The safety and efficacy of other emerging anticancer drugs.

Recently, the FDA (Food and Drug Administration, US Food and Drug Administration) and a New York-based unicorn company Flatiron (flat iron) focused on health data analysis, trying to use real-world data to prove immunotherapy and The safety and efficacy of other emerging anticancer drugs.

Flatiron has already received huge investments from Google Ventures and Roche. The two companies have invested $81 million and $175 million in two rounds of investment, supporting the unlisted start-ups, which gives the company a valuation. It has exceeded 1 billion.

Previously, Flatiron has used its data analysis capabilities to provide FDA with accurate medical platform support. The company currently has two analytical tools, ONCOAnalytics and ONCOEMR, the former focusing on cancer analysis and the latter on cancer-specific electronic medical record systems.

According to reports, the first publicly disclosed project between Flatiron and the FDA is focused on non-small cell lung cancer (NSCLC) research, including Opdivo and Merck on Bristol-Myers Squibb (BMY), which has been approved by the FDA. (MRK) Keytruda treatment of NSCLC drugs. In addition to clinical research, the FDA hopes to better assess the actual performance of these two tumor-immune star drugs based on actual real-world data.

This is because, based on real-world evidence analysis, the FDA can provide a broader assessment of the safety and efficacy of Opdivo and Keytruda, providing a more detailed picture that cannot be seen in clinical trial data.

Mao Spear, chief scientific officer of Huada Gene, told the First Financial Reporter: "Flatiron is unique and is the first company in the industry to start analyzing data on cancer outcomes. The amount of data it collects is beyond the reach of other companies. ."

Xu Chuanbo, product manager of Grail, the newly established blood diagnostics company of the world's largest genetic monitoring platform, told the First Financial Reporter: "What Flatiron is doing is the most interesting direction in the industry." It is understood that Grail's blood detection technology It will be used by the first users in 2019.

Amy Abernethy, chief medical officer and senior vice president of oncology at Flatiron, said in a statement: "Only 4% of adult American cancer populations participate in clinical trials, so as a supplier, we are currently The difficulty is that the results represent only a small percentage of patients' clinical decisions. This means that it is almost impossible to estimate whether treatment will work, nor to predict all potential side effects of the treatment, or to decide which treatment should be used first. ”

The issue raised by Abernesh was also the reason why founders Nat Turner and Zack Weinberg decided to set up the health care IT company. The two worked at Google, and when they left to start looking for the next project, they tried to use technology skills to improve cancer treatment. At the time, they found that registration of clinical trials was a major problem. To solve this problem, we must turn our attention to the analytical tools for solving cancer treatment data. Currently, Flatiron is already building a web-based cloud computing data integration platform for cancer.

Mussel

Fresh Half Shell Mussel Meat,Half Shell Mussel Meat,Frozen Cooked Mussel Meat,Frozen Mussel

Shengsi Huali Aquatic Products Co.,Ltd , https://www.mytilus-edulis.com